JPH07503457A - 光学的に純粋な（ｓ）−ロメフロキサシンを用いた感染症治療の方法と組成物 - Google Patents

光学的に純粋な（ｓ）−ロメフロキサシンを用いた感染症治療の方法と組成物

Info

Publication number: JPH07503457A
Authority: JP; Japan
Prior art keywords: lomefloxacin; composition; pharmaceutically acceptable; amount; side effects
Prior art date: 1991-11-27
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

JP5510220A

Other languages

English (en)

Japanese (ja)

Inventor

ダブリュ．ヤング，ジェームス

Original Assignee

セプラコア，インコポレーテッド

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1991-11-27

Filing date

1992-11-25

Publication date

1995-04-13

1992-11-25 Application filed by セプラコア，インコポレーテッド filed Critical セプラコア，インコポレーテッド

1995-04-13 Publication of JPH07503457A publication Critical patent/JPH07503457A/ja

Status Pending legal-status Critical Current

Links

229960002422 lomefloxacin Drugs 0.000 title claims description 72
239000000203 mixture Substances 0.000 title claims description 56
238000000034 method Methods 0.000 title claims description 31
208000035473 Communicable disease Diseases 0.000 title claims description 12
ZEKZLJVOYLTDKK-UHFFFAOYSA-N lomefloxacin Chemical compound FC1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNC(C)C1 ZEKZLJVOYLTDKK-UHFFFAOYSA-N 0.000 claims description 45
230000000694 effects Effects 0.000 claims description 25
208000015181 infectious disease Diseases 0.000 claims description 21
150000003839 salts Chemical class 0.000 claims description 19
239000003242 anti bacterial agent Substances 0.000 claims description 11
230000003115 biocidal effect Effects 0.000 claims description 8
208000036487 Arthropathies Diseases 0.000 claims description 7
208000018522 Gastrointestinal disease Diseases 0.000 claims description 7
206010019233 Headaches Diseases 0.000 claims description 7
208000012659 Joint disease Diseases 0.000 claims description 7
206010000059 abdominal discomfort Diseases 0.000 claims description 7
239000003937 drug carrier Substances 0.000 claims description 7
231100000869 headache Toxicity 0.000 claims description 7
206010020751 Hypersensitivity Diseases 0.000 claims description 6
208000013016 Hypoglycemia Diseases 0.000 claims description 5
239000002775 capsule Substances 0.000 claims description 5
230000002218 hypoglycaemic effect Effects 0.000 claims description 5
208000019423 liver disease Diseases 0.000 claims description 5
230000005976 liver dysfunction Effects 0.000 claims description 5
206010046306 Upper respiratory tract infection Diseases 0.000 claims description 4
238000009472 formulation Methods 0.000 claims description 4
208000000059 Dyspnea Diseases 0.000 claims description 3
206010013975 Dyspnoeas Diseases 0.000 claims description 3
206010057190 Respiratory tract infections Diseases 0.000 claims description 3
238000001990 intravenous administration Methods 0.000 claims description 3
208000020029 respiratory tract infectious disease Diseases 0.000 claims description 3
208000019206 urinary tract infection Diseases 0.000 claims description 3
208000001647 Renal Insufficiency Diseases 0.000 claims description 2
238000001802 infusion Methods 0.000 claims description 2
201000006370 kidney failure Diseases 0.000 claims description 2
QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 claims 2
230000005856 abnormality Effects 0.000 claims 2
230000008468 bone growth Effects 0.000 claims 2
208000000857 Hepatic Insufficiency Diseases 0.000 claims 1
206010022678 Intestinal infections Diseases 0.000 claims 1
230000004064 dysfunction Effects 0.000 claims 1
239000000825 pharmaceutical preparation Substances 0.000 claims 1
229940127557 pharmaceutical product Drugs 0.000 claims 1
230000037317 transdermal delivery Effects 0.000 claims 1
SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 26
150000001875 compounds Chemical class 0.000 description 15
239000004480 active ingredient Substances 0.000 description 14
241000894006 Bacteria Species 0.000 description 13
239000003826 tablet Substances 0.000 description 13
229940088710 antibiotic agent Drugs 0.000 description 9
210000004027 cell Anatomy 0.000 description 9
230000000844 anti-bacterial effect Effects 0.000 description 8
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
238000002360 preparation method Methods 0.000 description 8
241000282412 Homo Species 0.000 description 7
239000003814 drug Substances 0.000 description 7
229940079593 drug Drugs 0.000 description 7
230000001580 bacterial effect Effects 0.000 description 6
239000002552 dosage form Substances 0.000 description 6
230000003902 lesion Effects 0.000 description 6
208000024891 symptom Diseases 0.000 description 6
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 5
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
239000002253 acid Substances 0.000 description 5
239000008187 granular material Substances 0.000 description 5
239000008101 lactose Substances 0.000 description 5
239000007788 liquid Substances 0.000 description 5
239000000243 solution Substances 0.000 description 5
-1 troches Substances 0.000 description 5
229920002261 Corn starch Polymers 0.000 description 4
230000002159 abnormal effect Effects 0.000 description 4
210000000845 cartilage Anatomy 0.000 description 4
239000008120 corn starch Substances 0.000 description 4
229940099112 cornstarch Drugs 0.000 description 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
230000003628 erosive effect Effects 0.000 description 4
239000004615 ingredient Substances 0.000 description 4
210000004698 lymphocyte Anatomy 0.000 description 4
235000019359 magnesium stearate Nutrition 0.000 description 4
239000002609 medium Substances 0.000 description 4
244000005700 microbiome Species 0.000 description 4
230000011164 ossification Effects 0.000 description 4
239000000843 powder Substances 0.000 description 4
239000007787 solid Substances 0.000 description 4
238000006467 substitution reaction Methods 0.000 description 4
208000035143 Bacterial infection Diseases 0.000 description 3
208000001860 Eye Infections Diseases 0.000 description 3
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
229920002472 Starch Polymers 0.000 description 3
230000009471 action Effects 0.000 description 3
208000022362 bacterial infectious disease Diseases 0.000 description 3
230000008901 benefit Effects 0.000 description 3
210000004369 blood Anatomy 0.000 description 3
239000008280 blood Substances 0.000 description 3
238000012258 culturing Methods 0.000 description 3
201000010099 disease Diseases 0.000 description 3
208000011323 eye infectious disease Diseases 0.000 description 3
230000003907 kidney function Effects 0.000 description 3
238000002156 mixing Methods 0.000 description 3
230000003287 optical effect Effects 0.000 description 3
150000007530 organic bases Chemical class 0.000 description 3
230000002829 reductive effect Effects 0.000 description 3
230000008085 renal dysfunction Effects 0.000 description 3
230000004044 response Effects 0.000 description 3
235000019698 starch Nutrition 0.000 description 3
239000000725 suspension Substances 0.000 description 3
230000009885 systemic effect Effects 0.000 description 3
210000001635 urinary tract Anatomy 0.000 description 3
GSDSWSVVBLHKDQ-UHFFFAOYSA-N 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 description 2
241000589291 Acinetobacter Species 0.000 description 2
208000030090 Acute Disease Diseases 0.000 description 2
229920001817 Agar Polymers 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 2
GSDSWSVVBLHKDQ-JTQLQIEISA-N Levofloxacin Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
230000001154 acute effect Effects 0.000 description 2
239000000443 aerosol Substances 0.000 description 2
239000008272 agar Substances 0.000 description 2
239000011230 binding agent Substances 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
206010006451 bronchitis Diseases 0.000 description 2
239000007894 caplet Substances 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
231100000135 cytotoxicity Toxicity 0.000 description 2
230000003013 cytotoxicity Effects 0.000 description 2
230000003247 decreasing effect Effects 0.000 description 2
239000002270 dispersing agent Substances 0.000 description 2
238000011156 evaluation Methods 0.000 description 2
230000009931 harmful effect Effects 0.000 description 2
239000003701 inert diluent Substances 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
150000007529 inorganic bases Chemical class 0.000 description 2
238000010253 intravenous injection Methods 0.000 description 2
210000001853 liver microsome Anatomy 0.000 description 2
229960003814 lomefloxacin hydrochloride Drugs 0.000 description 2
239000000314 lubricant Substances 0.000 description 2
238000005259 measurement Methods 0.000 description 2
150000007522 mineralic acids Chemical class 0.000 description 2
238000012986 modification Methods 0.000 description 2
230000004048 modification Effects 0.000 description 2
238000000465 moulding Methods 0.000 description 2
MHWLWQUZZRMNGJ-UHFFFAOYSA-N nalidixic acid Chemical compound C1=C(C)N=C2N(CC)C=C(C(O)=O)C(=O)C2=C1 MHWLWQUZZRMNGJ-UHFFFAOYSA-N 0.000 description 2
229960000210 nalidixic acid Drugs 0.000 description 2
231100000252 nontoxic Toxicity 0.000 description 2
230000003000 nontoxic effect Effects 0.000 description 2
229960001180 norfloxacin Drugs 0.000 description 2
229960001699 ofloxacin Drugs 0.000 description 2
150000007524 organic acids Chemical class 0.000 description 2
235000005985 organic acids Nutrition 0.000 description 2
239000008194 pharmaceutical composition Substances 0.000 description 2
230000003389 potentiating effect Effects 0.000 description 2
239000000047 product Substances 0.000 description 2
AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 2
230000000241 respiratory effect Effects 0.000 description 2
230000029058 respiratory gaseous exchange Effects 0.000 description 2
210000002345 respiratory system Anatomy 0.000 description 2
210000003491 skin Anatomy 0.000 description 2
210000004872 soft tissue Anatomy 0.000 description 2
239000008107 starch Substances 0.000 description 2
239000008223 sterile water Substances 0.000 description 2
210000002784 stomach Anatomy 0.000 description 2
239000000126 substance Substances 0.000 description 2
238000012360 testing method Methods 0.000 description 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
230000002485 urinary effect Effects 0.000 description 2
WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 1
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 1
LOJNFONOHINEFI-UHFFFAOYSA-N 4-[4-(2-hydroxyethyl)piperazin-1-yl]butane-1-sulfonic acid Chemical compound OCCN1CCN(CCCCS(O)(=O)=O)CC1 LOJNFONOHINEFI-UHFFFAOYSA-N 0.000 description 1
NALQROWQYPHQOG-UHFFFAOYSA-N 4-oxo-2-piperazin-1-yl-3h-quinoline-3-carboxylic acid Chemical compound OC(=O)C1C(=O)C2=CC=CC=C2N=C1N1CCNCC1 NALQROWQYPHQOG-UHFFFAOYSA-N 0.000 description 1
102000009027 Albumins Human genes 0.000 description 1
108010088751 Albumins Proteins 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
206010060968 Arthritis infective Diseases 0.000 description 1
206010051728 Bone erosion Diseases 0.000 description 1
206010065687 Bone loss Diseases 0.000 description 1
241000589513 Burkholderia cepacia Species 0.000 description 1
QZOWOXMSIRWSSR-UHFFFAOYSA-N CCC1=C2C(=CC=C1)NC(=O)C(C2=O)C(=O)O Chemical compound CCC1=C2C(=CC=C1)NC(=O)C(C2=O)C(=O)O QZOWOXMSIRWSSR-UHFFFAOYSA-N 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
208000017667 Chronic Disease Diseases 0.000 description 1
206010010904 Convulsion Diseases 0.000 description 1
201000003883 Cystic fibrosis Diseases 0.000 description 1
RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
230000007018 DNA scission Effects 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
239000006145 Eagle's minimal essential medium Substances 0.000 description 1
208000004232 Enteritis Diseases 0.000 description 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
229920001917 Ficoll Polymers 0.000 description 1
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
206010017964 Gastrointestinal infection Diseases 0.000 description 1
239000007995 HEPES buffer Substances 0.000 description 1
241000606768 Haemophilus influenzae Species 0.000 description 1
208000001953 Hypotension Diseases 0.000 description 1
206010022773 Intracranial pressure increased Diseases 0.000 description 1
201000008197 Laryngitis Diseases 0.000 description 1
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
208000032376 Lung infection Diseases 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
208000009233 Morning Sickness Diseases 0.000 description 1
MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
229910002651 NO3 Inorganic materials 0.000 description 1
241000588652 Neisseria gonorrhoeae Species 0.000 description 1
NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
208000037581 Persistent Infection Diseases 0.000 description 1
201000007100 Pharyngitis Diseases 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
102000003946 Prolactin Human genes 0.000 description 1
108010057464 Prolactin Proteins 0.000 description 1
206010050662 Prostate infection Diseases 0.000 description 1
208000028017 Psychotic disease Diseases 0.000 description 1
206010038687 Respiratory distress Diseases 0.000 description 1
206010062255 Soft tissue infection Diseases 0.000 description 1
241000191967 Staphylococcus aureus Species 0.000 description 1
241000191963 Staphylococcus epidermidis Species 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
208000036142 Viral infection Diseases 0.000 description 1
208000034850 Vomiting in pregnancy Diseases 0.000 description 1
KSHPUQQHKKJVIO-UHFFFAOYSA-N [Na].[Zn] Chemical compound [Na].[Zn] KSHPUQQHKKJVIO-UHFFFAOYSA-N 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
239000013543 active substance Substances 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
150000001450 anions Chemical class 0.000 description 1
230000000845 anti-microbial effect Effects 0.000 description 1
239000003430 antimalarial agent Substances 0.000 description 1
238000003556 assay Methods 0.000 description 1
244000052616 bacterial pathogen Species 0.000 description 1
JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
229940077388 benzenesulfonate Drugs 0.000 description 1
SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical class OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
229940050390 benzoate Drugs 0.000 description 1
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
230000036765 blood level Effects 0.000 description 1
210000000988 bone and bone Anatomy 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
150000001722 carbon compounds Chemical class 0.000 description 1
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
150000001768 cations Chemical class 0.000 description 1
230000030833 cell death Effects 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
229960002023 chloroprocaine Drugs 0.000 description 1
229960003677 chloroquine Drugs 0.000 description 1
WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 1
OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
229960001231 choline Drugs 0.000 description 1
210000000349 chromosome Anatomy 0.000 description 1
229960003405 ciprofloxacin Drugs 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
239000003086 colorant Substances 0.000 description 1
239000007891 compressed tablet Substances 0.000 description 1
238000007906 compression Methods 0.000 description 1
230000006835 compression Effects 0.000 description 1
238000013270 controlled release Methods 0.000 description 1
230000036461 convulsion Effects 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
230000034994 death Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
239000008355 dextrose injection Substances 0.000 description 1
230000003205 diastolic effect Effects 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
238000001035 drying Methods 0.000 description 1
210000005069 ears Anatomy 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
210000002615 epidermis Anatomy 0.000 description 1
229940012017 ethylenediamine Drugs 0.000 description 1
210000003527 eukaryotic cell Anatomy 0.000 description 1
210000001508 eye Anatomy 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
229940050410 gluconate Drugs 0.000 description 1
239000003979 granulating agent Substances 0.000 description 1
210000004013 groin Anatomy 0.000 description 1
229940047650 haemophilus influenzae Drugs 0.000 description 1
229930195733 hydrocarbon Natural products 0.000 description 1
150000002430 hydrocarbons Chemical class 0.000 description 1
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
238000011081 inoculation Methods 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000011835 investigation Methods 0.000 description 1
230000002427 irreversible effect Effects 0.000 description 1
238000002955 isolation Methods 0.000 description 1
210000001503 joint Anatomy 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
229960001375 lactose Drugs 0.000 description 1
229910052744 lithium Inorganic materials 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
230000003908 liver function Effects 0.000 description 1
208000012866 low blood pressure Diseases 0.000 description 1
210000004705 lumbosacral region Anatomy 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
239000000463 material Substances 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
229960003194 meglumine Drugs 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
239000013081 microcrystal Substances 0.000 description 1
210000001589 microsome Anatomy 0.000 description 1
239000007932 molded tablet Substances 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
230000035772 mutation Effects 0.000 description 1
VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
201000009240 nasopharyngitis Diseases 0.000 description 1
210000001331 nose Anatomy 0.000 description 1
150000002894 organic compounds Chemical class 0.000 description 1
239000006201 parenteral dosage form Substances 0.000 description 1
239000008188 pellet Substances 0.000 description 1
235000019371 penicillin G benzathine Nutrition 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
210000003800 pharynx Anatomy 0.000 description 1
239000000902 placebo Substances 0.000 description 1
229940068196 placebo Drugs 0.000 description 1
230000010287 polarization Effects 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
230000035935 pregnancy Effects 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
229940097325 prolactin Drugs 0.000 description 1
229960003712 propranolol Drugs 0.000 description 1
210000002307 prostate Anatomy 0.000 description 1
201000007094 prostatitis Diseases 0.000 description 1
LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 description 1
150000003248 quinolines Chemical class 0.000 description 1
125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
VMXUWOKSQNHOCA-LCYFTJDESA-N ranitidine Chemical compound [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 description 1
229960000620 ranitidine Drugs 0.000 description 1
238000000926 separation method Methods 0.000 description 1
230000001568 sexual effect Effects 0.000 description 1
238000007493 shaping process Methods 0.000 description 1
206010040872 skin infection Diseases 0.000 description 1
239000008354 sodium chloride injection Substances 0.000 description 1
230000002269 spontaneous effect Effects 0.000 description 1
239000007921 spray Substances 0.000 description 1
239000012086 standard solution Substances 0.000 description 1
239000008174 sterile solution Substances 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
MNQYNQBOVCBZIQ-JQOFMKNESA-A sucralfate Chemical compound O[Al](O)OS(=O)(=O)O[C@@H]1[C@@H](OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](COS(=O)(=O)O[Al](O)O)O[C@H]1O[C@@]1(COS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)O1 MNQYNQBOVCBZIQ-JQOFMKNESA-A 0.000 description 1
229960004291 sucralfate Drugs 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
229940095064 tartrate Drugs 0.000 description 1
231100000462 teratogen Toxicity 0.000 description 1
239000003439 teratogenic agent Substances 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
231100001274 therapeutic index Toxicity 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
210000003708 urethra Anatomy 0.000 description 1
208000000143 urethritis Diseases 0.000 description 1
230000009385 viral infection Effects 0.000 description 1
239000007762 w/o emulsion Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents

Landscapes

Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Communicable Diseases (AREA)
Epidemiology (AREA)
Oncology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

JP5510220A 1991-11-27 1992-11-25 光学的に純粋な（ｓ）−ロメフロキサシンを用いた感染症治療の方法と組成物 Pending JPH07503457A (ja)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US79924391A	1991-11-27	1991-11-27
US799,243		1991-11-27
PCT/US1992/010142 WO1993010785A1 (en)	1991-11-27	1992-11-25	Methods and compositions for treating infection using optically pure (s)-lomefloxacin

Publications (1)

Publication Number	Publication Date
JPH07503457A true JPH07503457A (ja)	1995-04-13

Family

ID=25175406

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP5510220A Pending JPH07503457A (ja)	1991-11-27	1992-11-25	光学的に純粋な（ｓ）−ロメフロキサシンを用いた感染症治療の方法と組成物

Country Status (5)

Country	Link
EP (1)	EP0614364A4 (de)
JP (1)	JPH07503457A (de)
AU (2)	AU3147493A (de)
CA (1)	CA2124443A1 (de)
WO (1)	WO1993010785A1 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6075024A (en)	1991-11-27	2000-06-13	Sepracor Inc.	Methods for treating infection using optically pure (S)-lomefloxacin

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU553415B2 (en) *	1983-09-19	1986-07-17	Abbott Japan Co., Ltd.	6-fluoro-1-4-dihydro-4-oxo-7-substituted piperazinyl- quinoline-3-carboxylic acids
JPS60190777A (ja) *	1984-03-12	1985-09-28	Hokuriku Seiyaku Co Ltd	光学活性な６，８−ジフルオロ−１，４−ジヒドロ−４−オキソ−７−置換ピペラジニルキノリン−３−カルボン酸誘導体
JPS618538A (ja) *	1984-06-25	1986-01-16	Shimizu Constr Co Ltd	工場等における空調機構
JP2676521B2 (ja) *	1988-03-22	1997-11-17	北陸製薬株式会社	キノロンカルボン酸化合物ｉ型結晶の製造法
JPH02115182A (ja) *	1988-10-21	1990-04-27	Yoshitomi Pharmaceut Ind Ltd	光学活性ピリドンカルボン酸化合物

1992
- 1992-11-25 EP EP9292925403A patent/EP0614364A4/de not_active Ceased
- 1992-11-25 CA CA002124443A patent/CA2124443A1/en not_active Abandoned
- 1992-11-25 WO PCT/US1992/010142 patent/WO1993010785A1/en not_active Ceased
- 1992-11-25 AU AU31474/93A patent/AU3147493A/en not_active Abandoned
- 1992-11-25 JP JP5510220A patent/JPH07503457A/ja active Pending
1997
- 1997-03-07 AU AU15151/97A patent/AU1515197A/en not_active Abandoned

Also Published As

Publication number	Publication date
WO1993010785A1 (en)	1993-06-10
EP0614364A4 (de)	1994-10-19
CA2124443A1 (en)	1993-06-10
AU3147493A (en)	1993-06-28
AU1515197A (en)	1997-05-22
EP0614364A1 (de)	1994-09-14

Publication	Publication Date	Title
US5476854A (en)	1995-12-19	Methods and compositions for treating bacterial infection using optically pure (R)-lomefloxacin
US5200558A (en)	1993-04-06	S(+)-ibuprofen-L-amino acid and S(+)-ibuprofen-D-amino acid as onset-hastened enhanced analgesics
JP2641745B2 (ja)	1997-08-20	結晶性β−ラクタム水和物
JP2024508737A (ja)	2024-02-28	疾患を治療するための方法および医薬組成物
CA2703971A1 (en)	2009-05-07	Stabilized pediatric suspension of carisbamate
JP2007507436A (ja)	2007-03-29	脳梗塞の予防及び治療用医薬品の製造におけるｌ−ブチルフタリドの使用
AU723788B2 (en)	2000-09-07	Methods and compositions for treating infection using optically pure (S)-lomefloxacin
KR102141519B1 (ko)	2020-08-06	치료 방법
RU2098094C1 (ru)	1997-12-10	Способ приготовления водной суспензии и водный глазной препарат
JPH07503457A (ja)	1995-04-13	光学的に純粋な（ｓ）−ロメフロキサシンを用いた感染症治療の方法と組成物
HUT50440A (en)	1990-02-28	Process for producing pharmaceutical compositions for treating schizophrenia
JPH07501546A (ja)	1995-02-16	光学的に純粋な（ｒ）−ロメフロキサシンを用いた感染症治療の方法と組成物
US9987257B2 (en)	2018-06-05	Pediatric oral suspension formulations of amoxicillin and clavulanate potassium and method for using same
US20060160887A1 (en)	2006-07-20	Medicinal composition
AU3575299A (en)	1999-08-19	Methods and compositions for treating infection using optically pure (R)-lomefloxacin
AU3575399A (en)	1999-08-19	Methods and compositions for treating infection using optically pure (S)-lomefloxacin
CN113797109A (zh)	2021-12-17	沙星类药物的抗衰老用途
MXPA01000466A (en)	2001-09-07	Method of treatment